6-O-methyl-β-D-glucose | 24436-14-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-O-methyl-β-D-glucose
• 英文别名: (2~{R},3~{R},4~{S},5~{S},6~{R})-6-(methoxymethyl)oxane-2,3,4,5-tetrol；(2R,3R,4S,5S,6R)-6-(methoxymethyl)oxane-2,3,4,5-tetrol
• CAS: 24436-14-4
• 化学式: C₇H₁₄O₆
• 分子量: 194.185
• InChiKey: QWJKEQVWXSYDJA-XUUWZHRGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-O-methyl-β-D-glucose 生成 6-O-methyl-α-D-glucose
  参考文献：
  名称：

  REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246

  摘要：

  DOI：
• 作为产物：
  描述：

  6-O-methyl-α-D-glucose 生成 6-O-methyl-β-D-glucose
  参考文献：
  名称：

  REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246

  摘要：

  DOI：

文献信息

• Triterpenoid saponins from leaves of Pittosporum undulatum
  作者：Ryuichi Higuchi、Toshihiro Fujioka、Masayo Iwamoto、Tetsuya Komori、Toshio Kawasaki、Erich V. Lassak

  DOI：10.1016/0031-9422(83)80166-6

  日期：——
• REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246
  作者：REUBEN, JACQUES

  DOI：——

  日期：——
• PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE
  申请人：HET NEDERLANDS KANKER INSTITUUT (The Netherlands Cancer Institute)

  公开号：EP1686959B1

  公开（公告）日：2009-06-24
• Pharmaceutical formulations employing short-chain sphingolipids and their use
  申请人：Veldman J. Robert

  公开号：US20070082855A1

  公开（公告）日：2007-04-12

  This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C 8 -GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C 6 -SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipidis selected from compounds of the following formula: wherein: R 1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R 1 is independently: an O-linked (optionally N-(C 1-4 alkyl)-substituted amino)-C 1-6 alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)-C 1-6 alkyl-phosphate group; R 2 is independently C 3-9 alkyl, and is independently unsubstituted or substituted; R 3 is independently C 7-19 alkyl, and is independently unsubstituted or substituted; R 4 is independently —H, —OH, or —O—C 1-4 alkyl; R N is independently —H or C 1-4 alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R 5 is —H; if the bond marked with an alpha (α) is a single bond, then R 5 is —H or —OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG2000-DSPE). The present invention also pertains to methods for the preparation and use of such formulations.
• METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS
  申请人：VELDMAN Robert J.

  公开号：US20110150984A1

  公开（公告）日：2011-06-23

  This invention pertains to methods of increasing the bioavailability and/or cellular uptake of an amphiphilic drug when administered parenterally, which method comprises the step of parenterally co-administering the drug with a short-chain sphingolipid as described herein.